Will bromodomain inhibitors and PROTACs make an impact?
Before we get to the World Congress in Lung Cancer (WCLC) taking place this weekend, I want to take a moment to reflect on some of the things we have learn over the last few weeks.
It’s time for a reader mailbag as we answer reader questions on the recent MYC mini-series, as well as covering bromodomain inhibitors (what’s going on there?) and discuss a new PROTAC compound in early development that looks quite interesting.
We also explain why that is the case…
To learn more from out latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers